William Hahn, M.D., Ph.D.
William Hahn is an institute member of the Broad Institute’s Cancer Program. He is a medical oncologist, and an associate professor at the Dana–Farber Cancer Institute and Harvard Medical School. At Dana-Farber, he also serves as the chair of the Executive Committee for Research, chief of the Division of Molecular and Cellular Oncology, and director of the Center for Cancer Genome Discovery.
Hahn’s work as a physician-scientist involves both the care of cancer patients and biomedical research directed toward a greater understanding of the mechanisms involved in malignant transformation. At the Broad, he leads efforts to apply functional genomic approaches to cancer. He is a founding member and co-principal investigator of The RNAi Consortium (TRC), a Broad Institute-based effort that has developed tools for somatic cell genetics in mammalian cells. Hahn’s own lab is engaged in using RNAi, CRISPR and ORF libraries to identify cancer vulnerabilities.
Hahn has been the recipient of several honors and awards, including the Wilson S. Stone Award from MD Anderson Cancer Center for outstanding research in cancer, the Howard Temin Award from the National Cancer Institute, and the Gill-Siminion Prize for Mentoring. Hahn is also a Ho-Am Laureate in Medicine, and was elected to the American Society of Clinical Investigation in 2005 and the Association of American Physicians in 2013.
Hahn holds a B.A. from Harvard University, and an M.D. and Ph.D. from Harvard Medical School. He completed clinical training in internal medicine at Massachusetts General Hospital and medical oncology at Dana-Farber. He conducted his postdoctoral studies in the lab of Robert Weinberg at the Whitehead Institute for Biomedical Research.